DynaDes - Your partner for selective protein inhibitors.
At DynaDes, we design pre-clinical drugs using innovative and proven, proprietary computational methods that account for protein dynamics and solvation effects. Combined with our in-house designed compound libraries and synthesis resources, our unique approach is remarkably efficient in generating novel, highly selective and potent drug candidates.
From the target definition up to clinical stage entry, DynaDes focuses on a streamlined approach to provide patented compounds addressing unmet medical needs.
Our current pipeline of products target the ATP-binding and allosteric sites of protein kinases, epigenetic targets and protein-protein interaction sites of proteins implicated in cancer. The particular selectivity of our compounds, coupled with their potency, solubility and toxicity profiles, renders them attractive for further development by our partner companies.
If you are interested in research positions, please click here